Morningstar19h
Merck in Cancer Licensing Pact With LaNova Medicines
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an ...
Hosted on MSN1d
What it will take to create the next CSL or Telix Pharmaceuticals
It’s a good place to develop, with generous government incentives, including a Research & Development (R&D) rebate. There are ...
manilatimes2d
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
She previously served as Chief Executive Officer at Harpoon Therapeutics until the company's acquisition by Merck in early 2024. In addition to Ms. Eastland's appointment, Ingmar Bruns, M.D., has been ...
TMCnet6d
The Galien Foundation Honors 2024 Prix Galien Award Recipients
Winners received prestigious award in recognition of latest innovations in advancement in life sciences ...
manilatimes6d
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in ...